Receipt: https://pmc.ncbi.nlm.nih.gov/articles/PMC13601825/ Read: 2026-11-12, curl with browser user agent, HTML converted to text, HTTP 200 Note: 2026 review: human IV NAD+ evidence is sparse; lists reported side effects. (Text converted from HTML; the superscript plus in NAD+ is joined to the word.) --- Abstract Background Nicotinamide adenine dinucleotide (NAD+) is a major coenzyme critically involved in cellular metabolism, mitochondrial function, DNA repair, and stress-response signaling. Age-associated decline in NAD+ levels has generated interest in NAD+-augmenting strategies; however, recent large-scale human data indicate that whole-blood NAD+ concentrations do not decline with healthy aging per se . Despite increasing commercial use of IV NAD+ therapy in wellness settings, the clinical evidence supporting its efficacy and long-term safety remains limited. Methods Literature published between January 2018 and March 2026 was identified via PubMed and Google Scholar searches. Search terms were applied symmetrically across all target compounds and administration routes. Studies were included if they reported human clinical data on IV NAD+ or IV NAD+ precursor administration, or if they provided directly relevant mechanistic or safety evidence. Mechanistic and foundational studies published before 2018 were selectively incorporated via citation tracking of key included articles. Results Available human evidence is sparse and consists primarily of small uncontrolled studies, observational investigations, and isolated case reports. Short-term IV NAD+ or NMN administration has been associated with transient increases in circulating NAD+ levels and changes in selected biomarkers related to oxidative stress, inflammation, and cellular metabolism. Limited exploratory reports have also described self-reported improvements in sleep-related outcomes and neurologic symptoms. However, the clinical significance of these findings remains uncertain due to small sample sizes, lack of placebo controls, heterogeneous methodologies, and short follow-up durations. Reported adverse effects include nausea, cramping, flushing, and chest discomfort, while long-term safety data are lacking. Conclusion Current evidence regarding IV NAD+ therapy remains preliminary and insufficient to support routine clinical or wellness use. Although mechanistic and translational studies provide biological rationale for NAD+ augmentation, robust conclusions regarding efficacy, durability of benefit, optimal dosing, and long-term safety cannot currently be established. Larger randomized controlled trials with standardized protocols and clinically meaningful endpoints are required before IV NAD+ therapy can be considered evidence-based clinical practice. Keywords: clinical wellness settings, cognitive function, intravenous, metabolic health, NAD+ therapy, nicotinamide mononucleotide, oral 1. Introduction Nicotinamide adenine dinucleotide (NAD+) is one of the most recognized fundamental coenzymes in physiology, involved in cellular energy metabolism, redox reactions, DNA repair, epigenetic regulation, and cellular signaling pathways ( Xie et al., 2020 ). NAD+ is a crucial component of mitochondrial function and cellular homeostasis, involved in more than 500 enzymatic reactions and being the indispensable substrate for three key enzyme families: sirtuins, poly(ADP-ribose) polymerases, and cyclic ADP-ribose synthases (CD38/CD157) ( Verdin, 2015 ). NAD+ progressively declines over time, making it central to age-related metabolic dysfunction, mitochondrial dysfunction, senescence of the cell, as well as increased susceptibility to chronic diseases ( Yoshino et al., 2018 ). This widely held premise deserves critical scrutiny; however, Trętowicz et al. (2026) , in a large-scale cro [...] , NAD+ therapy, nicotinamide mononucleotide, oral 1. Introduction Nicotinamide adenine dinucleotide (NAD+) is one of the most recognized fundamental coenzymes in physiology, involved in cellular energy metabolism, redox reactions, DNA repair, epigenetic regulation, and cellular signaling pathways ( Xie et al., 2020 ). NAD+ is a crucial component of mitochondrial function and cellular homeostasis, involved in more than 500 enzymatic reactions and being the indispensable substrate for three key enzyme families: sirtuins, poly(ADP-ribose) polymerases, and cyclic ADP-ribose synthases (CD38/CD157) ( Verdin, 2015 ). NAD+ progressively declines over time, making it central to age-related metabolic dysfunction, mitochondrial dysfunction, senescence of the cell, as well as increased susceptibility to chronic diseases ( Yoshino et al., 2018 ). This widely held premise deserves critical scrutiny; however, Trętowicz et al. (2026) , in a large- [...] [...] ( Verdin, 2015 ). NAD+ progressively declines over time, making it central to age-related metabolic dysfunction, mitochondrial dysfunction, senescence of the cell, as well as increased susceptibility to chronic diseases ( Yoshino et al., 2018 ). This widely held premise deserves critical scrutiny; however, Trętowicz et al. (2026) , in a large-scale cross-sectional cohort study, demonstrated that whole-blood NAD+ concentrations were not independently associated with chronological age once disease burden and comorbidity were accounted for. Janssens et al. (2022) similarly argued that the clinical relevance of NAD+ decline should be evaluated in the context of metabolic dysfunction rather than aging per se . These findings carry practical implications for patient selection in IV NAD+ trials: if age alone does not reliably predict NAD+ deficiency, trials may benefit from screening participants by whole-blood NAD+ status rather than by age bracket alone, to enrich for individuals most likely to demonstrate measurable responses to r [...] [...] able responses to repletion therapy. The realization that NAD+ depletion is a property of aging/age-associated pathologies has led to intensive investigation of therapeutic avenues to restore NAD+ homeostasis ( Rajman et al., 2018 ). NAD+ can be synthesized across multiple biosynthetic pathways, which include the de novo pathway of tryptophan, the Preiss-Handler pathway of nicotinic acid, and the salvage pathway from nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) ( Yoshino et al., 2018 ). Within this cascade, a salvage pathway mediated by nicotinamide phosphoribosyltransferase (NAMPT) has been found to dominate mammalian tissues and should be the focus of NAD+ augmentation strategies ( Ratia et al., 2023 ). Supplementation strategies aimed at increasing NAD+ availability have attracted growing scientific interest because age-related decline in NAD+ has been associated with mitochondrial dysfunction, impaired metabolic regulation, and altered cellular st [...] [...] applied symmetrically across all target compounds and administration routes. Studies were included if they reported human clinical data on IV NAD+ or IV NAD+ precursor administration, or if they provided directly relevant mechanistic or safety evidence. Mechanistic and foundational studies published before 2018 were selectively incorporated via citation tracking of key included articles. Results Available human evidence is sparse and consists primarily of small uncontrolled studies, observational investigations, and isolated case reports. Short-term IV NAD+ or NMN administration has been associated with transient increases in circulating NAD+ levels and changes in selected biomarkers related to oxidative stress, inflammation, and cellular metabolism. Limited exploratory reports have also described self-reported improvements in sleep-related outcomes and neurologic symptoms. However, the clinical significance of these findings remains uncertain due to small sample sizes, lack of placebo controls, heterogeneous methodologies, and [...] [...] ance to NAD+ biology or IV administration were excluded. Studies were screened first by title and abstract, and then by full-text review. 2.2. Quality and certainty of evidence The overall quality of evidence relating to IV NAD+ therapy remains low. Most available human data derive from small, uncontrolled studies, observational reports, and isolated case reports with limited follow-up durations. Randomized placebo-controlled trials specifically evaluating IV NAD+ administration are currently lacking. As a result, substantial risks of selection bias, placebo effects, confounding, and overinterpretation of biomarker findings remain. Because of substantial differences in study design, population characteristics, interventions, and reported outcomes, findings were synthesized qualitatively rather than quantitatively. Particular attention was given to study design, sample size, the presence or absence of control groups, the duration of follow-up, and the clinical applicability of the reported fi [...] [...] linical significance is uncertain ( Gan, 2022 ; Liao et al., 2024 ). These observations have encouraged investigators to explore alternative delivery methods, including intravenous (IV) administration, which theoretically bypasses gastrointestinal absorption and first-pass metabolism ( Benjamin and Crews, 2024 ; Reyna et al., 2026 ). Although IV administration may achieve rapid systemic exposure, direct evidence demonstrating superiority over oral supplementation is currently lacking ( Kimura et al., 2022 ). Furthermore, many IV infusion protocols described in commercial settings have not undergone formal clinical validation, and substantial variation exists in dosing strategies, infusion duration, and accompanying supplements. Several commercial concerns have emerged regarding the expansion of IV NAD+ therapy in wellness settings before standardized protocols, long-term safety data, or guideline-supported indications are established. Much of the currently available literat [...] [...] ed self-reported improvements in sleep-related outcomes and neurologic symptoms. However, the clinical significance of these findings remains uncertain due to small sample sizes, lack of placebo controls, heterogeneous methodologies, and short follow-up durations. Reported adverse effects include nausea, cramping, flushing, and chest discomfort, while long-term safety data are lacking. Conclusion Current evidence regarding IV NAD+ therapy remains preliminary and insufficient to support routine clinical or wellness use. Although mechanistic and translational studies provide biological rationale for NAD+ augmentation, robust conclusions regarding efficacy, durability of benefit, optimal dosing, and long-term safety cannot currently be established. Larger randomized controlled trials with standardized protocols and clinically meaningful endpoints are required before IV NAD+ therapy can be considered evidence-based clinical practice. Keywords: clinical wellness settings, cognitive function, intravenous, metabolic [...] [...] y signaling ( Kane et al., 2024 -preprint). Early human studies evaluating oral NAD+ precursors such as NR and NMN have reported changes in selected metabolic and inflammatory biomarkers, although findings remain inconsistent and clinical significance is uncertain ( Gan, 2022 ; Liao et al., 2024 ). These observations have encouraged investigators to explore alternative delivery methods, including intravenous (IV) administration, which theoretically bypasses gastrointestinal absorption and first-pass metabolism ( Benjamin and Crews, 2024 ; Reyna et al., 2026 ). Although IV administration may achieve rapid systemic exposure, direct evidence demonstrating superiority over oral supplementation is currently lacking ( Kimura et al., 2022 ). Furthermore, many IV infusion protocols described in commercial settings have not undergone formal clinical validation, and substantial variation exists in dosing strategies, infusion duration, and accompanying supplements. Several commercial concerns have emerged regar [...] [...] e alternative delivery methods, including intravenous (IV) administration, which theoretically bypasses gastrointestinal absorption and first-pass metabolism ( Benjamin and Crews, 2024 ; Reyna et al., 2026 ). Although IV administration may achieve rapid systemic exposure, direct evidence demonstrating superiority over oral supplementation is currently lacking ( Kimura et al., 2022 ). Furthermore, many IV infusion protocols described in commercial settings have not undergone formal clinical validation, and substantial variation exists in dosing strategies, infusion duration, and accompanying supplements. Several commercial concerns have emerged regarding the expansion of IV NAD+ therapy in wellness settings before standardized protocols, long-term safety data, or guideline-supported indications are established. Much of the currently available literature consists of small observational studies, uncontrolled investigations, mechanistic reports, and translational hypotheses rather than adequately powered randomized clinical trials ( Gindri et al., 2024 ; Sohouli et al., 2024 ). In addition, impor [...] [...] of infusion, a diluent formulation, infusion rate, and monitoring. Outpatient clinic infusions with monitoring have been described in published literature, but specific infusion rate and diluent information are not standardized and vary ( Braidy, 2018 ). Rapid IV NAD+ infusion can sometimes induce discomfort, flushing, or nausea according to anecdotal reports from clinical wellness settings where many practitioners prefer slow infusion rates extending from 2 to 4 h. Systematic dose-escalation studies and direct comparisons of different IV NAD+ doses remain lacking. The available studies used different protocols and doses, limiting meaningful dose–response comparisons. 4. Discussion This review highlights the considerable gap between the growing commercial adoption of IV NAD+ therapy and the limited quality of currently available clinical evidence. Although mechanistic studies provide a biologically plausible rationale for NAD+ augmentation, clinical evide [...] [...] n selected biomarkers related to oxidative stress, inflammation, and cellular metabolism. Limited exploratory reports have also described self-reported improvements in sleep-related outcomes and neurologic symptoms. However, the clinical significance of these findings remains uncertain due to small sample sizes, lack of placebo controls, heterogeneous methodologies, and short follow-up durations. Reported adverse effects include nausea, cramping, flushing, and chest discomfort, while long-term safety data are lacking. Conclusion Current evidence regarding IV NAD+ therapy remains preliminary and insufficient to support routine clinical or wellness use. Although mechanistic and translational studies provide biological rationale for NAD+ augmentation, robust conclusions regarding efficacy, durability of benefit, optimal dosing, and long-term safety cannot currently be established. Larger randomized controlled trials with standardized protocols and clinically meaningful endpoints are required before IV NAD+ ther [...] [...] + : n = 6; NR: n = 8) No No None No (retrospective; no pre-specified primary outcome) High Kimura et al. (2022) Open-label, exploratory safety study 10 (healthy adults) No No None Yes-safety and tolerability (primary endpoint) High Open in a new tab Short-term adverse effects reported during IV NAD+ administration have included nausea, abdominal discomfort, flushing, cramping, chest pressure, and infusion-related intolerance, particularly at faster infusion rates ( Reyna et al., 2026 ). In comparative observational data, IV NR appeared to be better tolerated than IV NAD+ itself, although the studies were small and exploratory ( Reyna et al., 2026 ). Further, NR was well tolerated at the daily oral dose of 2000 mg in a 12-week study in healthy men ( Dollerup et al., 2018 ). Several important uncertainties remain regarding chronic or repeated NAD+ augmentation. Because NAD+ participates in multiple metabolic and proliferative pathways, theoretical concern [...] [...] uration trials dominate Open in a new tab Abbreviations: ADPR, adenosine diphosphoribose; AE, adverse event; NAM, nicotinamide; NaMN, nicotinic acid mononucleotide; PK, pharmacokinetic. TABLE 2. Adverse events and safety data reported across IV NAD+ and IV NMN human studies. Study Route/Formulation Dose range n Adverse events reported Serious AEs Infusion-related reactions Notes on safety profile Braidy (2018) IV NAD+ 1,000 mg/day × 6 days 8 Mild flushing, transient nausea None reported Flushing; transient chest discomfort in some participants Small uncontrolled study with limited systematic safety assessment; findings should be interpreted cautiously Grant et al. (2019) IV NAD+ 750 mg over 6 h (∼3 μmol/min) 11 (8 NAD+ ; 3 saline control) No AEs observed during infusion; small changes in selected liver enzymes and bilirubin were reported but were not considered clinically significant None reported None observed Controlled pilot study with short-term follow-up; sm [...]